Physician profile
Arvind M Pai
NPI 1902833197
$959.50
in general payments reported to CMS, 2019-2025
15 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $105 · 2021: $217 · 2022: $131 · 2023: $220 · 2024: $18.28 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $392.49 | 2019-2023 | Xarelto |
| Abbott Laboratories | $133.23 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $121.86 | 2025 | Uptravi, Opsumit |
| Impulse Dynamics (USA) INC. | $49.88 | 2021-2022 | |
| Pfizer INC. | $45.55 | 2020 | |
| Bard Peripheral Vascular, INC. | $41.91 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.62 | 2023 | Jardiance |
| Novo Nordisk INC | $23.16 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.14 | 2022 | |
| Angiodynamics, INC. | $20.64 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $20.04 | 2025 | Austedo Xr |
| Kestra Medical Technology Services, INC. | $18.28 | 2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $16.12 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.05 | 2023 | |
| Merck Sharp & Dohme LLC | $13.53 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.